San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

Morgan Stanley upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from an equal weight rating to an overweight rating in a research note published on Friday, MarketBeat.com reports. Morgan ...

The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...

Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...

Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...